Ikarian Capital, LLC Relmada Therapeutics, Inc. Call Options Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $8.7 Million - $17.6 Million	475,300 Added 158.43%	775,300 $28.7 Million
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $1.59 Million - $2.93 Million	96,600 Added 47.49%	300,000 $5.7 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $171,390 - $227,070	5,800 Added 2.94%	203,400 $6.51 Million
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $6.23 Million - $7.76 Million	197,600 New	197,600 $6.96 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.